Takeda Pharmaceutical is set to buy Nycomed for 9.6 billion $13.7 billion in cash, in Japan’s second-largest outbound MA deal and its largest healthcare MA deal.
Takeda is already Japan’s largest pharmaceutical company and the acquisition will consolidate its position by some margin. But, equally, the deal will add to Takeda’s drug pipeline and its geographical reach.
Nycomed is well established in Europe and some high-growth emerging markets, with the majority of its revenues from prescription pharmaceutical products and a smaller presence in over-the-counter products. This complements Takeda’s presence in the Japanese and US markets and immediately doubles Takeda’s European sales. Nycomed’s more than 2.8...
¬ Haymarket Media Limited. All rights reserved.
